Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| The Pharmakon debt facility of $275 million bolsters our strong balance sheet, which will enable us to extend our cash run rate through the end of 2026 |
| This new non-dilutive debt facility of $275 million bolsters our strong balance sheet, which will enable us to extend our cash runway through the end of 2026 |
| But again, we were really anticipating that we would see this level of support and interest from the HCP and the patient community and that is really very encouraging |
| We are pleased with this quick uptake, which reflects strong demand |
| I would like to highlight a few financial items this quarter, including our strong cash position and our operating expenses |
| And that’s really tracking as we had expected, so we’re very pleased with that as well |
| And so we think it’s favorable as far as the read-through to the class |
| But at a high level, I can say that we were pleased with the safety |
| We are pleased to share that we have seen strong initial demand for SKYCLARYS from patients and their healthcare providers |
| Last year in Europe, we received a positive opinion from pediatric committee on a proposed pediatric investigation plan |
| In closing, we are pleased with the approval of SKYCLARYS, the first and only drug to treat patients with FA |
| We are pleased with early payer coverage of SKYCLARYS tracking as we expected for a rare, progressive and devastating disease with no other approved treatment options |
| So again, I think we’re confident that the control strategy of adding and increasing the specification limit for this specific impurity is the right thing |
| Since the imbalance favored placebo, the statistically significant results of the primary analysis favoring Omav treatment despite these imbalances indicate a robust efficacy outcome |
| Lastly, critical to our launch success and quarter, our patient promise, we continue to facilitate payer coverage, access and affordability through payer education and robust programs designed to minimize or eliminate patient out-of-pocket cost burden |
| We are really pleased with this early demand and expected that patients and HCPs would be actively engaged upon approval |
| So they – we’re very fortunate that our analytical method – our validated analytical method is able to detect this |
| And so at this time, I think we’re very confident in our manufacturing process and the lots produced |
| We are pleased that we should be able to provide thorough responses and requested information back to the EMA within a standard response period |
| We are encouraged by the significant interest from patients and healthcare providers to begin SKYCLARYS treatment and are working to have commercial drug in the channel as expedition as possible |
| And as Dawn mentioned, since we’re very excited with the current full start and first two months to reach 500 patients, we believe that point could come pretty quickly after launch |
| Along with the savings from the funds planned for bardoxolone development and our anticipated SKYCLARYS revenues, we believe that we’re on a path to self sustainability |
| Immediately following approval, Reata created a strong market presence and engaged the FA community with our first branded booth at important Neurology Conferences, including the Muscular Dystrophy Association, the National Ataxia Foundation and the American Academy of Neurology |
| So yes, I think we’re in very good shape to answer those questions, yes |
| Centers of Excellence and implementing plans to support the needs of these highly important accounts |
| These resources will permit us to relentlessly pursue our mission to bring life-changing medicine to patients with severe diseases |
| As of march 31, 2023, we maintained a solid balance sheet with approximately $321 million in cash, cash equivalents and marketable debt securities |
| Cemdomespib was well tolerated with no safety signals, drug discontinuations or SAEs |
| Warren Huff I think we’re hopeful that we’ll see good enrollment there |
| It is differentiated from other molecules and that it not only reduces pain, but it also restores sensation and models associated with loss of sensation |
| Statement |
|---|
| Of course, we’re disappointed with the results of the AYAME study and the need discontinued development of bardoxolone for the treatment of patients with CKD |
| Despite the disappointing outcome of our CKD program, the safety data from AYAME provide important data for the broader Nrf2 activator class |
| This poses a significant regulatory challenge |
| It had just been below the reporting threshold of basically 0.1% |
| There are many factors that could cause results to differ from expectations, including those noted in the Company’s SEC filings |
| In regard to the impact of AYAME on our CKD programs, a major challenge for bardoxolone CK development program has been the use of eGFR as a surrogate that is intended to predict ESRD |
| While mitochondrial dysfunction may not be the initiating event, it appears to be a common downstream pathway that results in subsequent loss of function and regeneration in areas that are affected |
| While we are disappointed with AYAME results, our decision to discontinue by bardoxolone development and enter into the amended agreement with Blackstone allows us to refocus our resources and over $100 million in capital towards our future pipeline and programs that were previously planned for CKD development |
| It resolves some overhang from the BEACON trial |
| If you recall, in the pivotal Omav trial imbalances in baseline characteristics, such as history of cardiomyopathy and longer GAA1 Repeat Length, favored placebo patients with less sick and had less advanced disease |
| Sorry, asking more question again on this impurity issue |
| But once again, we just – the eGFR increase was not maintained, which explains why |
| I guess, is the supply that you’ve manufactured put at risk at all by the discovery of this impurity? Warren Huff We don’t believe so |
| And so we don’t know if investigators had a difficult time managing patients as their kidney function approached ESRD if there were concerns about the large loss that was observed |
| Because there was no improvement in ESRD events and the regulatory implications of that, we and KKC have decided to discontinue our bardoxolone development activities and we’ve decided to refocus our capital and resources on our other programs |
| As a consequence, we and KKC are terminating our CKD programs |
| But it’s a slow low single-digit number and it’s also capped |
| Yes, I would say no news is good news |
| Initially, there was an increase, why there’s separation of 30% and 40% declines, but ultimately not in the ESRD events |
Please consider a small donation if you think this website provides you with relevant information